Prime Minister Justin Trudeau announced the opening of a major vaccine production plant in Toronto Thursday— part of Canada’s efforts to build up the domestic biomanufacturing sector in the aftermath of the COVID-19 pandemic.
The new Sanofi facility is the largest in Canada and is expected to significantly increase Canada’s domestic production of pediatric and adult vaccines for whooping cough, diphtheria and tetanus.
During the COVID-19 pandemic, it became clear that Canada’s domestic production capacity was insufficient to respond to the pandemic emergency, leaving Canada to rely on imported vaccines.
Sanofi, a global biopharmaceutical company, received $415 million from Canada and another $55 million from the Ontario government, to build a flu vaccine and pandemic preparedness plant at its Toronto campus by 2026.
- N.S. long-term care strike could soon end after tentative deal reached: CUPE
- Security tight as Walk for Israel in Toronto draws tens of thousands
- Teen driver, 2 motorcycle riders dead after multi-vehicle collision in Ontario
- Heading to the beach this summer? Here’s how to stay safe in Ontario waters
The company says that facility will be ready in 2027.
Get weekly health news
Between May 2020 and April 2022, Canada promised more than $1.3 billion for 12 new or expanded biomanufacturing plants to make vaccines and antibody treatments.
Comments
Want to discuss? Please read our Commenting Policy first.